Detecting Abnormal Heart Rhythms in Stroke Patients

DELTA (Detecting and Predicting Atrial Fibrillation in Post-Stroke Patients)

Recruiting Observational Study
Stroke, Ischemic
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
55 and older
Sex
Any
Study type
Observational
Participants needed
500 (estimated)
Sponsor
Emory University · Other
Who this trial is looking for

This trial is looking for adults over 55 who have had a stroke with an unknown cause. Participants will wear a smartwatch for 30 days to help monitor their heart rhythm.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am 55 years old or older.
  • I have had an ischemic stroke with an unknown cause.
  • I am receiving follow-up treatment at the Emory Stroke Clinic.
  • I have been prescribed extended cardiac monitoring.
  • I can give informed consent.
  • I understand English and how to use the study wrist device.

You may not be able to join if

  • I am younger than 55 years old.
  • I do not need extended cardiac monitoring.
  • I cannot understand English or follow instructions for the wrist device.
  • I have structural valve disease.
  • I have endocarditis.
  • I have aortic arch atheroma larger than 3 mm.
  • I have a condition that makes me prone to blood clots.
  • I am on lifelong anticoagulation medication.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
Atrial Fibrillation (AF) is an abnormal heart rhythm. Because AF is often asymptomatic, it often remains undiagnosed in the early stages. Anticoagulant therapy greatly reduces the risks of stroke in patients diagnosed with AF. However, diagnosis of AF requires long-term ambulatory monitoring procedures that are burdensome and/or expensive. Smart devices (such as Apple or Fitbit) use light sensors…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adults 55 years of age or older. * Post-discharge with diagnostic of index ischemic stroke with uncertain cause. * Subject must be treated at the Emory Stroke Clinic for follow-up treatment. * Subject must be prescribed a clinical extended cardiac monitoring. * Subject or thei…
Contacts

Xiao Hu, PhD

404-712-8520

xhu40@emory.edu

CONTACT

Corey Williams

404-251-4060

corey.williams2@emory.edu

CONTACT